Physician profile
Brooke Mcguire
NPI 1780952127
$3,324.15
in general payments reported to CMS, 2019-2025
29 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $705 · 2022: $608 · 2023: $725 · 2024: $670 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $838.89 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $594.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $593.90 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $146.29 | 2021-2025 | Airsupra, Breztri |
| Abbott Laboratories | $144.09 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.47 | 2021-2025 | Xifaxan |
| Amgen INC. | $121.99 | 2021-2025 | Evenity, Prolia |
| Teva Pharmaceuticals USA, INC. | $95.58 | 2022-2024 | Ajovy, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $85.30 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $69.52 | 2021-2022 | |
| Glaxosmithkline, LLC. | $45.06 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Neos Therapeutics, LP | $43.97 | 2021-2022 | |
| Boston Scientific Corporation | $41.42 | 2024 | Watchman Flx |
| Kowa Pharmaceuticals America, INC. | $35.18 | 2021-2025 | Zoryve |
| Pfizer INC. | $33.57 | 2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $31.75 | 2022-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $31.05 | 2021-2022 | |
| Ibsa Pharma INC. | $27.91 | 2023 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $26.00 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $23.15 | 2022 | |
| Amarin Pharma, INC. | $21.73 | 2021 | |
| Genentech USA, INC. | $19.82 | 2021 | |
| Hologic Sales and Service, LLC | $19.76 | 2023 | Aptima, Thinprep 2000 Processor |
| Mannkind Corporation | $17.73 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.80 | 2023 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.39 | 2021 | |
| Agile Therapeutics, INC. | $16.33 | 2021 | |
| Janssen Biotech, INC. | $16.10 | 2024 | Tremfya |
| Clarus Therapeutics INC. | $10.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Mcguire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.